SPECTRUM FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th

Core Viewpoint - A class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. for allegedly making false and misleading statements regarding its Pinnacle Study of poziotinib for lung cancer treatment, which was less favorable than presented to investors [3][7]. Allegation Details - The lawsuit claims that Spectrum's public statements during the class period from March 17, 2022, to September 22, 2022, were false and materially misleading [3][7]. - The Pinnacle Study results were not as positive as the company portrayed, leading to investor losses [3]. Next Steps - Investors who purchased Spectrum shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is September 24, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].